The monitoring of NLR, PLR, NT-proBNP, cTn I, and ST2/IL-33R in DTC/−T2DM patients receiving 131I therapy over a long period may help to identify those at risk of developing cardiac complications, including heart failure, myocardial complications, and chronic cardiomyopathies. The gene discussed is IL1RL1; the disease is heart failure.